We specialize in bringing orphan and ultra-orphan drugs to market in the UK and EU. Our team ensures that therapies meet all regulatory and safety standards, supporting approvals, post-marketing surveillance, and access frameworks.
Orphan Drug Commercialization
Our commercialization capabilities include:
Regulatory submissions and post-approval compliance (MHRA, EMA)
Market introduction strategies tailored to niche indications
Cross-border launch planning and lifecycle management
Commercial supply readiness and medical education at launch
With a focus on unmet clinical needs, we ensure each product launch is built around real patient impact.
Patient Access & Support Programs
Removing Barriers Between Patients and Life-Changing Treatments
For patients with rare diseases, access can be the single most critical component of care. Aegerion provides a range of programs and services designed to reduce delays, improve adherence, and help patients and families navigate the healthcare system.
